2. Maternal adverse events.
| Study | Tachycardia | Mouth dryness | Nausea | Vomiting | Dizziness | Cervical laceration | Giddiness | Blood loss | Flushing of face | Headache |
|
Ajmera 2006 (Drotaverine hydrochloride) |
2.7% | 0 | 0 | 0 | 0 | 1.3% | 1.3% | Not reported | 0 | 4% |
|
Ajmera 2006 (Valethamtate bromide) |
14.6% | 2.7% | 0 | 0 | 0 | 0 | 0 | Not reported | 5.3% | 2.7% |
|
Ajmera 2006 (Placebo) |
5.3% | 1.3% | 0 | 0 | 0 | 4% | 4% | Not reported | 0 | 2.7% |
| Al Matari 2007 | Did not report on maternal adverse events | |||||||||
|
Al Qahtani 2011 (Hyoscine butyl bromide) |
PPH¹: 0/52; Tear: 2/50 | |||||||||
|
Al Qahtani 2011 (Placebo) |
PPH: 0/45; Tear: 0/45 | |||||||||
| Azari 2010 | Did not report on maternal adverse events | |||||||||
| Batukan 2006 | Women receiving Valethamate bromide experienced more dizziness and mouth dryness than women receiving placebo | |||||||||
|
Cromi 2011 (Rociverine) |
No maternal side effects reported | 300 mL (100‐1400) | ||||||||
|
Cromi 2011 (Placebo) |
No maternal side effects reported | 350 mL (50‐2000) | ||||||||
| Dahal 2013 | Dryness of mouth, vomiting, tachycardia and retention of urine were more pronounced in the valethamate bromide group than in the drotaverine hydrochloride and control groups | |||||||||
|
Gupta 2008 (Drotaverine hydrochloride) |
20% of participants experienced adverse events, the main ones being nausea and vomiting | |||||||||
|
Gupta 2008 (Hyoscine butyl bromide) |
10% | 0 | Main complaint | Main complaint | 24% of participants experienced adverse effects | |||||
|
Gupta 2008 (Placebo) |
No reported maternal adverse events | |||||||||
|
Khosla 2003 (Valethamate bromide) |
16% | 4% | Not reported | 4% | Not reported | |||||
|
Khosla 2003 (Drotaverine hydrochloride) |
No maternal adverse events reported | |||||||||
|
Khosla 2003 (Control) |
No maternal adverse events reported | |||||||||
| Kuruvila 1992 | Maternal pulse rate > 110/min observed in significantly more women receiving Valethamate bromide. Flushing of face and dryness of mouth not statistically significant between groups. | |||||||||
|
Madhu 2010 (Drotaverine hydrochloride) |
4% | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 10% |
|
Madhu 2010 (Valethamate bromide) |
81.6% | 20% | 0 | 0 | 0 | 0 | 0 | 0 | 10% | 2% |
|
Madhu 2010 (Control) |
6.30% | 4.2% | 0 | 0 | 0 | 0 | 2.1% | 0 | 0 | 0 |
|
Makvandi 2010 (Hyoscine butyl bromide) |
Mean heart rate:83.34 beats/min, SD:10.56 Mean systolic BP: 108.78 mmHg, SD: 12.34 |
|||||||||
|
Makvandi 2010 (Placebo) |
Mean heart rate:86.65 beats/min, SD:12.87 Mean systolic BP: 110.09 mmHg, SD:13.67 |
|||||||||
|
Mukaindo 2010 (Hyoscine butyl bromide) |
1 patient reported transient palpitations PPH in 5.7% participants |
|||||||||
|
Mukaindo 2010 (Placebo) |
No adverse events reported PPH in 7.3% of participants |
|||||||||
|
Raghavan 2008 (Hyoscine butyl bromide) |
Mild tachycardia, dryness of mouth and vomiting | |||||||||
|
Raghavan 2008 (Valethamate bromide) |
Mild tachycardia, dryness of mouth and vomiting | |||||||||
|
Raghavan 2008 (No medication) |
No adverse events reported | |||||||||
|
Samuels 2007 (Hyoscine butyl bromide) |
0 | 0 | 0 | 0 | 0 | 0 | 0 | 150 mL (50‐1800 mL) | 0 | 0 |
|
Samuels 2007 (Placebo) |
0 | 0 | 0 | 0 | 0 | 0 | 0 | 150 mL (50‐550 mL) | 0 | 0 |
| Sekhavat 2012 | No adverse events reported | |||||||||
|
Sharma 2001 (Drotaverine hydrochloride) |
4% | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4% |
|
Sharma 2001 (Valethamate bromide) |
20% | 10% | 0 | 0 | 0 | 0 | 0 | 0 | 4% | 0 |
|
Sharma 2001 (Control) |
4% | 0 | 0 | 0 | 0 | 0 | 6% | 0 | 0 | 4% |
|
Singh 2004 (Drotaverine hydrochloride) |
18% had atonic PPH | |||||||||
|
Singh 2004 (Control) |
2.5% had atonic PPH | |||||||||
|
Warke 2003 (Camylofin dihydrochloride) |
1% | 5% | 5% | 6% | 0 | 2% | 0 | 0 | 0 | 0 |
|
Warke 2003 (Control) |
0 | 0 | 0 | 0 | 0 | 2% | 0 | 0 | 0 | 0 |
|
Yilmaz 2009 (Valethamte bromide) |
21.3% | 14.9% | 14.9% | 8.5% | 12.8% | 2.1% | 0 | 0 | 0 | 0 |
|
Yilmaz 2009 (Control) |
4.1% | 0 | 10.2% | 6.1% | 4.1% | 0 | 0 | 0 | 0 | 0 |
¹PPH: postpartum haemorrhage